BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37261088)

  • 1. FXR agonist GW4064 enhances anti-PD-L1 immunotherapy in colorectal cancer.
    Lu L; Jiang YX; Liu XX; Jin JM; Gu WJ; Luan X; Guan YY; Zhang LJ
    Oncoimmunology; 2023; 12(1):2217024. PubMed ID: 37261088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
    Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity.
    Cheng LS; Zhu M; Gao Y; Liu WT; Yin W; Zhou P; Zhu Z; Niu L; Zeng X; Zhang D; Fang Q; Wang F; Zhao Q; Zhang Y; Shen G
    Cell Mol Biol Lett; 2023 May; 28(1):47. PubMed ID: 37259060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXR
    You W; Li L; Sun D; Liu X; Xia Z; Xue S; Chen B; Qin H; Ai J; Jiang H
    Cancer Immunol Res; 2019 Jun; 7(6):990-1000. PubMed ID: 30975694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GW4064 enhances the chemosensitivity of colorectal cancer to oxaliplatin by inducing pyroptosis.
    Guo J; Zheng J; Mu M; Chen Z; Xu Z; Zhao C; Yang K; Qin X; Sun X; Yu J
    Biochem Biophys Res Commun; 2021 Apr; 548():60-66. PubMed ID: 33631675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvia mitiorrhiza Bunge aqueous extract attenuates infiltration of tumor-associated macrophages and potentiates anti-PD-L1 immunotherapy in colorectal cancer through modulating Cox2/PGE2 cascade.
    Song M; Qian C; Zhang T; Tang Y; Zhou Y; Wei Z; Wang A; Zhong C; Zhao Y; Lu Y
    J Ethnopharmacol; 2023 Nov; 316():116735. PubMed ID: 37286115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesoid X Receptor Agonist GW4064 Protects Lipopolysaccharide-Induced Intestinal Epithelial Barrier Function and Colorectal Tumorigenesis Signaling through the αKlotho/βKlotho/FGFs Pathways in Mice.
    Liu HM; Chang ZY; Yang CW; Chang HH; Lee TY
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Butyrate facilitates immune clearance of colorectal cancer cells by suppressing STAT1-mediated PD-L1 expression.
    Zhang Y; Tao Y; Gu Y; Ma Q
    Clinics (Sao Paulo); 2023; 78():100303. PubMed ID: 37931529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene augmented nuclear-targeting sonodynamic therapy via Nrf2 pathway-based redox balance adjustment boosts peptide-based anti-PD-L1 therapy on colorectal cancer.
    Wan G; Chen X; Wang H; Hou S; Wang Q; Cheng Y; Chen Q; Lv Y; Chen H; Zhang Q
    J Nanobiotechnology; 2021 Oct; 19(1):347. PubMed ID: 34715867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endostatin induces normalization of blood vessels in colorectal cancer and promotes infiltration of CD8+ T cells to improve anti-PD-L1 immunotherapy.
    Chu XD; Bao H; Lin YJ; Chen RX; Zhang YR; Huang T; He JS; Huangfu SC; Pan YL; Ding H
    Front Immunol; 2022; 13():965492. PubMed ID: 36389685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.
    Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M
    Front Immunol; 2022; 13():794684. PubMed ID: 35720386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer.
    Liu C; Wang X; Qin W; Tu J; Li C; Zhao W; Ma L; Liu B; Qiu H; Yuan X
    Cancer Commun (Lond); 2023 Apr; 43(4):435-454. PubMed ID: 36855844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adiponectin determines farnesoid X receptor agonism-mediated cardioprotection against post-infarction remodelling and dysfunction.
    Xia Y; Zhang F; Zhao S; Li Y; Chen X; Gao E; Xu X; Xiong Z; Zhang X; Zhang J; Zhao H; Wang W; Wang H; Guo Y; Liu Y; Li C; Wang S; Zhang L; Yan W; Tao L
    Cardiovasc Res; 2018 Aug; 114(10):1335-1349. PubMed ID: 29668847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer.
    Gao Y; Bi D; Xie R; Li M; Guo J; Liu H; Guo X; Fang J; Ding T; Zhu H; Cao Y; Xing M; Zheng J; Xu Q; Xu Q; Wei Q; Qin H
    Signal Transduct Target Ther; 2021 Nov; 6(1):398. PubMed ID: 34795206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low molecular weight heparin synergistically enhances the efficacy of adoptive and anti-PD-1-based immunotherapy by increasing lymphocyte infiltration in colorectal cancer.
    Quan Y; He J; Zou Q; Zhang L; Sun Q; Huang H; Li W; Xie K; Wei F
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37597850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPARγ agonist pioglitazone enhances colorectal cancer immunotherapy by inducing PD-L1 autophagic degradation.
    Jia X; Qian J; Chen H; Liu Q; Hussain S; Jin J; Shi J; Hou Y
    Eur J Pharmacol; 2023 Jul; 950():175749. PubMed ID: 37105516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic adenovirus H101 ameliorate the efficacy of anti-PD-1 monotherapy in colorectal cancer.
    Huang L; Zhao H; Shan M; Chen H; Xu B; He Y; Zhao Y; Liu Z; Chen J; Xu Q
    Cancer Med; 2022 Dec; 11(23):4575-4587. PubMed ID: 35762456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of farnesoid X receptor agonist on adiponectin and its receptors].
    Xin X; Zhong M; Zhang S; Peng Y; Zhu W; Zhang Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2014 Jan; 34(1):109-12. PubMed ID: 24463129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCL5-deficiency enhances intratumoral infiltration of CD8
    Zhang S; Zhong M; Wang C; Xu Y; Gao WQ; Zhang Y
    Cell Death Dis; 2018 Jul; 9(7):766. PubMed ID: 29991744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.